A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-08-02
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-26 (study day 44); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-12 (study day 60); relationship: not assessed
severe
assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-05-19 (study day 280); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-08-31 (study day 384); relationship: Y
Data queries
No data queries.